🇺🇸 FDA
Pipeline program

UB-221

UBP-A107-IgE

Phase 1 mab completed

Quick answer

UB-221 for Urticaria Chronic is a Phase 1 program (mab) at United Therapeutics Europe Ltd with 1 ClinicalTrials.gov record(s).

Program details

Company
United Therapeutics Europe Ltd
Indication
Urticaria Chronic
Phase
Phase 1
Modality
mab
Status
completed

Clinical trials